Medicine and Dentistry
Psoriasis
100%
Acneiform Eruption
80%
Genome Wide Association Study
80%
Pustular Psoriasis
80%
Acne Vulgaris
80%
Anakinra
80%
Placebo
80%
Treatment Option
80%
Atopic Dermatitis
80%
Therapeutic Drug Monitoring
80%
Risankizumab
80%
Monotherapy
80%
Odds Ratio
60%
Ethnic Groups
48%
Transforming Growth Factor Beta
40%
Diseases
39%
Interleukin 1
30%
Health Care Cost
26%
Clinician
26%
Biological Product
26%
Biological Therapy
23%
Inflammatory Disorder
20%
Cell Signaling Pathway
20%
Beta Cell
20%
Gene Linkage
20%
Treatment Response
16%
Endotype
16%
Prevalence
16%
Targeted Therapy
16%
Lichenoid
16%
Diagnostic Error
16%
Subgroup Analysis
16%
Erythema
16%
Registration Number
13%
Drug Exposure
13%
Remote Sensing
13%
Photograph
13%
Patient-Reported Outcome
13%
Primary Outcome
13%
Effective Treatment
13%
Cost-Effectiveness Analysis
13%
Pharmacokinetics
13%
Recurrent Disease
13%
Dermatitis
13%
Pustulosis Palmaris Et Plantaris
10%
Rare Disease
10%
Functional Disease
10%
Randomized Controlled Trial
10%
Arm
10%
Subcutaneous Injection
10%
Pharmacology, Toxicology and Pharmaceutical Science
Anakinra
80%
Pustular Psoriasis
80%
Placebo
80%
Interleukin 1
30%
Psoriasis
20%
Rare Disease
10%
Pustulosis palmoplantaris
10%
Functional Disease
10%
Subcutaneous Injection
10%
Diseases
10%
Randomized Controlled Trial
10%
